TSXV:BTI.H - Post by User
Post by
bfwon Nov 21, 2018 8:54pm
87 Views
Post# 29007921
007 - Gaucher’s disease
007 - Gaucher’s diseaseI can’t remember BTI having previously revealed that their next internal program was Type 2 Gaucher’s disease.
Current treatment is ERT that does not affect nervous system involvement.
A quick search says the market could be worth up to almost $900 million worldwide.
Anyway, it will be interesting to see them progress on this program (and hopefully beneficial for patients).
bfw